Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes

Diabetes

Volumn 49, Issue 12, 2000, Pages 2079-2086

  Parker, Janice C ^a   McPherson, R Kirk ^a   Andrews, Kim M ^a   Levy, Carolyn B ^a   Dubins, Jeffrey S ^a   Chin, Janice E ^a   Perry, Pia V ^a   Hulin, Bernard ^a   Perry, David A ^a   Inagaki, Taisuke ^a   Dekker, Koen A ^a   Tachikawa, Kiyoshi ^a   Sugie, Yutaka ^a   Treadway, Judith L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; CYCLIC AMP; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; RECEPTOR BLOCKING AGENT; SKYRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIVER CELL; LIVER MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033663923     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.12.2079     Document Type: Article

References (26)

1. Novel pharmacological and agrobiological activities
2. Expression cloning and signaling properties of the rat glucagon receptor
3. The human glucagon receptor encoding gene: Structure, cDNA sequence and chromosomal localization
4. 2+-dependent mechanism in glucagon-induced glucose output from the liver
5. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist
6. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats
7. Sub-chronic glucagon neutralisation improves diabetes in ob/ob mice
8. Cloning and expression of a human glucagon receptor
9. 2+ fluxes and phosphorylase activity in liver
10. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo
11. Diabetes and the α-cell
12. The essential role of glucagon in the pathogenesis of diabetes mellitus
13. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics
14. 9] glucagon amide, a glucagon antagonist
15. 2 identifies glucagon antagonists from weak partial agonists/antagonists
16. Pure glucagon antagonists: Biological activities and cAMP accumulation using phosphodiesterase inhibitors
17. CP-99,711 a non-peptide glucagon receptor antagonist
18. Discovery and structure-activity relationship of the first non-peptide competetive human glucagon receptor antagonists
19. BAY 27-9955, a novel non-peptide antagonist of glucagon binding to the glucagon receptor
20. Characterization of a novel, non-petptidyl antagonist of the human glucagon receptor
21. The effects of a specific glucagon antagonist on glucagon-stimulated glucose production
22. Mutagenicity and antibacterial activity of mycotoxins produced by Penicillium islandicum Sopp and Penicillium rugulosum
23. Mutagenicity of substituted anthraquinones in the Ames/Salmonella microsome system
24. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum Palmatum selectively inhibits the activity of casein kinase II as a competitive inhibitor
25. A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors